Introduction: Solitary fibrous tumors (SFTs) are rare mesenchymal neoplasms. Most follow a benign course, but a subset will recur or metastasize. Various risk stratification schemes have been proposed for SFTs, but none has been universally endorsed and few have focused on pleuropulmonary SFTs.
Introduction
Solitary fibrous tumors (SFTs) are uncommon but histologically distinctive mesenchymal neoplasms that are genetically characterized by a translocation leading to fusion of the NGFI-A binding protein 2 gene (NAB2) to the signal transducer and activator of transcription 6 gene (STAT6). 1, 2 Signal transducer and activator of transcription 6 (STAT6) immunohistochemistry is an effective surrogate to detect this genetic abnormality, and nuclear STAT6 expression is generally specific for SFTs. [3] [4] [5] [6] Although SFTs can occur at almost every anatomical site, they have a proclivity for the lung and pleura. Pleural SFTs were first described in 1870 by Wagner as "localized pleural mesothelioma," and it was once thought that they might be derived from the endothelium of pleural lymphatics. 7 The nomenclature of pleuropulmonary SFTs has evolved over time and includes a variety of antiquated names, such as localized fibrous tumor, localized mesothelioma, fibrous mesothelioma, benign mesothelioma, pleural fibroma, submesothelial fibroma, subserosal fibroma, and hemangiopericytoma. [8] [9] [10] Most SFTs from all sites follow a benign clinical course, but some examples will show aggressive behavior with recurrent disease, metastasis, and rarely death from disease. [11] [12] [13] [14] Various risk stratification schemes have been proposed for SFTs to predict which tumors have high risk of aggressive behavior. However, none has been officially endorsed by the WHO classifications of bone and soft tissue tumors or lung and pleural tumors. 15, 16 In 1989, England et al. studied 223 patients with pleuropulmonary SFT and proposed histologic criteria for malignancy, including high cellularity, more than 4 mitotic figures per 10 high-power fields (hpf), pleomorphism, hemorrhage, and necrosis. 17 Building on the criteria of England et al., de Perrot et al. 18 proposed a staging system for pleuropulmonary SFTs that divides patients into five stages on the basis of malignant histologic features, growth pattern, and presence of metastases. Demicco et al. 19 studied 110 cases of extra meningeal SFTs (abdominal, soft tissue, and pleuropulmonary tumors); they proposed a risk prediction model based on patient age, tumor size, and mitotic rate that is intended to predict metastatic potential and disease-specific mortality. Recently, a modification of this system was proposed to also include necrosis. 20 On the basis of a study of 113 cases, Tapias et al. 21 proposed a model for prediction of recurrence risk that is specific for pleuropulmonary SFTs. Similar to the Demicco system, it includes size, mitotic rate, and necrosis; however, it also considers hemorrhage, hypercellularity, tumor site, and growth pattern. Increased expression of Ki67, which is a marker of proliferative activity, has also been proposed to be indicative of malignant behavior in SFT. 22, 23 Our goals were to perform a retrospective and descriptive clinicopathological analysis of pleuropulmonary SFT, to identify features predictive of malignant behavior, and to validate and compare the performance of the various risk stratification models proposed for SFTs at this site.
Materials and Methods
The protocol for this study was approved by the Mayo Clinic Institutional Review Board. Patients who underwent surgery for SFTs of the lung or pleura at Mayo Clinic between 1940 and 2016 were identified by searching the pathology and surgical databases for the following diagnoses: SFT, hemangiopericytoma, malignant SFT, fibrous tumor of pleura, localized mesothelioma, and fibrous mesothelioma. Histologic sections were reviewed and diagnoses were confirmed. Tumor size was determined from the gross examination listed in the original pathology report. Immunohistochemistry was performed on formalin-fixed paraffin-embedded sections by using antibodies directed against CD34 protein (CD34) (clone QBEnd, Leica Novocastra, Newcastle upon Tyne, UK) and STAT6 (clone D-1, Santa Cruz Biotechnology, Dallas, TX). Ki67 (clone MIB-1, Dako, Glostrup, Denmark) analysis was also performed in a subset of cases (n ¼ 91); the remaining cases either did not have a block available (n ¼ 8), or demonstrated failure of staining (n ¼ 48) that was likely due to the age of the archived tissue blocks. The Ki67 labeling index was read manually, with estimation of the percentage of nuclei staining in the most proliferative area of the tumor (estimated to the nearest percent). STAT6 staining failed in seven cases and could not be performed in eight cases (no block available); in these cases, the diagnosis was confirmed by consensus review by two soft-tissue pathologists (J. M. B. and K. J. F.) with a very high degree of diagnostic certainty. If there was any diagnostic uncertainty about a case by either pathologist, it was excluded. CD34 staining failed in three cases and could not be performed in eight cases. Cases negative for STAT6 and CD34 were excluded, as they likely represented an alternative diagnosis.
Confirmed SFTs were subjected to a detailed histologic review, including mitotic count in the areas of highest proliferation and assessment of hypercellularity, severe atypia, necrosis, and epithelioid cytological features. Hypercellularity was defined as crowded, back-to-back, or overlapping tumor nuclei with absent or minimal intervening collagen. Marked atypia was defined as a threefold variation in nuclear size. Epithelioid change was defined as polygonal tumor cell shape with nuclear enlargement and moderate cytoplasm.
Demographics, radiographic findings, and follow-up data were collected from clinical records. The 5-year overall survival (OS) and 5-year progression-free survival (PFS) were estimated by using the Kaplan-Meier method. The outcome for PFS was defined as recurrence or metastasis (whichever occurred first), with death (any cause) being censored. Cox proportional hazards regression was performed to assess associations with OS and PFS; and hazard ratios (HRs), 95% confidence intervals (CIs), and likelihood ratio p values were reported. All tumors were risk-stratified by using the schemes proposed by de Perrot et al., Demicco et al. (original and modified), and Tapias et al. [18] [19] [20] 24 Details regarding the variables incorporated into the four risk stratification systems applied to our cohort are summarized in Table 1 . Risk scores between the modified Demicco and Tapias systems among recurrent patients were compared by using the McNemar test. p Values less than 0.05 were considered statistically significant. All analyses were performed with SAS software (version 9.4, SAS Institute Inc., Cary, NC).
Results
Demographic and histologic findings are summarized in Table 2 . The 147 study patients included 78 females (53%) with a median age of 61.5 years (range 25-87). Initial operative intervention with curative intent was performed in all patients; however, in two patients, debulking with gross residual disease was performed due to pleural dissemination. The remaining patients had negative surgical margins at initial resection. The surgical techniques included excision alone in 39 patients, excision with wedge resection in 79, lobectomy in 22, chest wall resection in four, and extended diaphragmatic resection in three. The median tumor size was 6.0 cm (range 0.8-35 cm). Pedunculated growth was present in 70 tumors (47.6%). Tumors were categorized as being of pleural origin in 97 patients, pulmonary origin in 43 patients, and indeterminate origin (both pleura and lung involved relatively equally) in seven. When tumors arising in the pleura were compared with those arising in the lung, the pleural tumors tended to be larger (median size 7 cm versus 4 cm [p ¼ 0.002]), but no differences were found in age (p ¼ 0.98) or mitotic rate (p ¼ 0.31). STAT6 immunohistochemistry was successfully performed in 132 patients, and the results were positive in all tested cases (100% [ Fig. 1]) . CD34 staining was successfully performed in 136 patients and was at least focally positive in 135 (99% [see Fig. 1]) . The patient with a negative result for CD34 was positive for STAT6. Severe atypia was present in 16 cases (10.9%), and necrosis was observed in 22 cases (15.0% [ Fig. 2]) .
The median follow-up time was 5.5 years (range 0-33). A total of 43 patients were known to have died at last follow-up, with five confirmed deaths from disease (3.4%). Disease progression occurred in 15 patients (10.2%): 11 patients had a recurrence, two patients had metastasis, and two patients had both. The sites of metastatic disease included bone marrow, contralateral lung, abdominal soft tissue, and pelvic soft tissue. The . One tumor that metastasized to the bone marrow had heterologous rhabdomyoblastic differentiation in both the primary tumor and the metastasis (Fig. 3 ). The primary tumor had areas of morphologically classical SFTs (positive for CD34 and STAT6), which transitioned to highly cellular areas with marked pleomorphism, necrosis, and increased mitotic activity. In these areas, rhabdomyoblastic differentiation could be observed as cells with abundant eosinophilic cytoplasm and eccentric nuclei, which had desmin, myogenin, and myoD1 expression. The metastasis in the bone marrow had a rhabdomyoblastic phenotype and lacked classical areas of SFT morphological features, but still contained STAT6-NAB2 fusion that was confirmed by clinical molecular testing. Adjuvant therapy was administered in four patients. Patient 1 was found to have a synchronous pelvic metastasis; the patient received 56 Gy of radiation to shrink the tumor from 6 cm to 5 cm and subsequently underwent abdominoperineal resection. The second patient received 50 Gy in 25 fractions after a third recurrence subsequent to a previous pneumonectomy with chest wall and diaphragm resection. She experienced metastasis to the abdomen 12 months later and was treated with adjuvant temozolomide and bevacizumab for four cycles with a mixed response. Patient 3 was treated with temozolomide and bevacizumab for first recurrence 12 months after her initial operation. She ultimately progressed during therapy and underwent surgery. She was treated with neoadjuvant radiotherapy (66 Gy) for a third recurrence in the mediastinum 12 months later, had a subsequent operation, and experienced recurrence again after 3 years. Patient 4 was treated with adjuvant cisplatin and 60 Gy of radiation on account of gross residual disease and experienced disease progression.
The results of univariate analysis of OS are presented in Table 3 The results of univariate analysis of PFS are presented in Table 4 Ki67 staining was performed in 91 patients (see Fig. 1 and Table 1 ). The median KiI67 labeling index was 2%, with a 75th percentile of 4% and 90th percentile of 7%. The labeling index was 1% or lower in 39 patients (42.9%). Twenty-five patients (27.5%) had a labeling index of 2%, whereas the labeling index was 3% or higher (ranging up to 20%) in 27 patients (29.7%). Only five patients had a Ki67 labeling index of 10% or higher. When recurrence within 5 years was considered (n ¼ 58 patients, excluding those with follow-up less than 5 years who did not experience recurrence), receiver operating characteristic analysis showed maximized sensitivity and specificity with a Ki67 index of 5% or higher; however, only 12% of patients in this analysis had a Ki67 labeling index of 5% or higher, thus limiting this analysis. When PFS among all patients with Ki67 labeling index data (n ¼ 91) was evaluated using a spline, the effect of Ki67 labeling index on the risk of recurrence showed a steady increase from 0% to 10%, at which point the risk appeared to plateau (noting very few data points with Ki67 labeling index ! 10); the HR for a 1% increase in Ki67 labeling index between 0% and 10% was 1.73 (95% CI: 1.35-2.38, p < 0.0001).
The breakdown of patients based on the four risk stratification systems is summarized in Table 2 . Compared with the original Demicco risk stratification, the modified system resulted in more patients in the lowrisk category (48.3% versus 67.3% [see Table 2 ]). With regard to the 22 patients with necrosis, the addition of necrosis to the modified Demicco risk stratification did not increase the predicted risk for any tumors (all remained within the same risk category with use of the original and modified Demicco systems); thus, the primary result of this modification seemed to be to decrease the risk prediction for tumors without necrosis. Of the 15 patients who experienced recurrence or metastases, 10 were at moderate to high risk according to the modified Demicco system and at high risk according to the Tapias system, two patients were classified as being at moderate to high risk according to the modified Demicco and at low risk according to the Tapias system, two were at high risk on the basis of the Tapias system and at low risk according to the modified Demicco system, and one patient was deemed at low risk according to both methods (the difference between the two methods was not significant). Kaplan-Meier curves for the four risk stratification systems are illustrated in Figure 4 (OS) and Figure 5 (PFS). Table 3] ). All three systems were significantly associated with PFS (all p < 0.001), with the modified Demicco system providing the best discrimination (C-statistic¼0.80 as compared with 0.78 for each of the other two [see Table 4 
Discussion
Our study further supports the variable clinical behavior of SFTs arising in the lung and pleura. 25 Most patients did well after surgical resection, but recurrence and/or metastasis occurred in about 10% of patients, which is very similar to what was observed by Diebold et al. 26, 27 This rate of recurrence was lower than that observed by Bylicki et al., but there are likely several differences in our cohorts that explain this difference: the number of stage IV tumors was higher in their study, they included several patients with inoperable metastatic disease at the time of diagnosis, and the number of patients who had an initial R0 resection was higher in our cohort. 28 In contrast, our recurrence rate is somewhat a Confidence interval or hazard ratio could not be estimated because of low or no events in reference category. CI, confidence interval; HR, hazard ratio; hpf, high-power field, Non Est., nonestimable.
higher than the 4% rate observed by Boddaert et al. but is likely within the range of statistical variation; their study also included a much higher rate of pedunculated tumors because only pleural tumors were included, which may contribute to this difference as well. 23 Ideally, patients at highest risk for recurrence or metastasis would be identified at the time of initial resection, so careful surveillance could be performed postoperatively. Numerous risk stratification schemes have been proposed, some of which can be applied to SFTs originating in many sites, including the soft tissue, abdominal cavity, and pleura, 19, 20 and some that are specific for tumors of the lung and pleura. 17, 18, 21, 24 Ideally, a standardized risk stratification system could be used across all soft-tissue and visceral sites to reduce confusion and variability introduced by using several different systems. However, it is not entirely clear whether the risk stratification schemes developed for SFTs from a variety of sites are sufficient to predict aggressive behavior for pleuropulmonary SFT, or whether the systems specifically developed for pleuropulmonary tumors may be more accurate and provide better clinical predictive power. One could argue that pleuropulmonary SFTs are a unique subset based on site-specific factors. SFTs at this site tend to be somewhat genetically unique as well, with particular frequency of the fusion variant NAB2 exon 4-STAT6 exon 2/4. 29 In our study, the systems proposed by de Perrot et al., Demicco et al., and Tapias et al. all predicted PFS in pleuropulmonary SFT. 18, 19, 21 However, only the Demicco and Tapias systems had an association with OS. Demicco's scoring system has two major advantages: it is the simplest system to apply with the least number of variables, and it may be applied in SFTs of all extrameningeal sites. Two of the variables in this system, age and tumor size, are objective measures that can be determined without histopathologic examination. The objectivity of these measures, along with the low number of variables, will likely lead to less interobserver variability in application of this system. Necrosis is an important component of grading of many soft-tissue sarcomas and was not part of the original SFT risk stratification proposed by Demicco et al. Very recently, a modification was proposed for this system to include necrosis, which enhanced its predictive power. 20 In our series, this modification served to reduce the risk prediction for patients without necrosis, leading to more patients in the low-risk group, which did seem to result in better separation of the risk groups.
In our series, the Tapias and Demicco systems performed similarly, with the modified Demicco system having a slightly better C-statistic (indicating slightly better discrimination). The Tapias system includes additional variables that are arguably more subjective (hemorrhage, hypercellularity, and growth pattern), which may introduce more interobserver variability into the application of this system. Additionally, the Tapias system is not applicable to SFTs outside the lung, so its use is limited to SFTs at this site. Pleural origin and growth pattern also may not be apparent to the examining pathologist if the tumor is narrowly excised, and input from the surgeon or radiologist may be required. A larger validation study of the Tapias system was performed by Lococo et al., 24 who concluded that the number of recurrences observed in the two clinical series was too low to represent a robust basis for a score system analysis owing to the low rate of recurrence, and they recommended larger studies to accrue more patients who have experienced recurrence or metastasis. They also proposed that other clinical features (chest wall invasion, malignant pleural effusion, etc.) probably deserve more attention in prognostic stratification after radical surgery. It is important to note that the different models have different end points for risk establishment. Although the Tapias model was developed to predict the risk of recurrence of SFT, the Demicco model was intended to predict metastatic risk and disease-specific mortality, because SFT recurrence may be related more to an incomplete resection than to aggressive tumor biology, with the caveat that the contribution of positive surgical margins to tumor recurrence has not been proven. For this reason and also given that metastatic disease and death from disease are relatively rare events in SFTs, it seemed most reasonable to include both recurrence and metastasis as end points in our study.
As needle core biopsies of SFTs become more widely available as a less invasive diagnostic tool, accurate diagnosis and grading become more challenging for the pathologist due to sampling issues. 30 Ki67 has been proposed as a possible surrogate marker in grading softtissue sarcomas on the basis of small biopsy samples, in which necrosis and mitotic activity cannot be accurately assessed. 30 A few prior studies have evaluated Ki67 labeling index in SFTs. Yokoi et al. reported a Ki67 labeling index of 1% or lower in benign SFTs, as defined by England's criteria. 31 Sun et al. 32 found a mean Ki67 labeling index of 1.9% (1.9 ± 0.43%) in benign SFTs and 6.11% (6.11 ± 1.05%) in malignant SFTs (p < 0.05), concluding that Ki67 is a potentially useful marker to predict the prognosis of pleural and extrapleural SFTs. In a study by Franzen et al., a Ki67 labeling index of 12% or more was indicative of malignant behavior 26 ; similarly, studies by Diebold et al. and Boddaert et al. found that a Ki67 labeling index of 10% or higher was associated with adverse behavior. 23, 27 However, these higher cutoffs will likely decrease the sensitivity of the Ki67 labeling index to predict aggressive behavior. In our study, Ki67 labeling index was found to correlate with PFS, with the cutoff of at least 2% expression. Although Ki67 labeling index may be unnecessary and redundant in resected tumors, when other features of aggressive behavior can be fully evaluated, it could be considered for use on small biopsy samples in selected cases when surgical excision may not be possible. Our Ki67 reading was performed manually; if digital reading were to be used, a more precise cutoff might be established.
Aggressive clinical behavior and worrisome histologic characteristics in SFTs have been associated with accrual of genetic events in addition to the transforming NAB2-STAT6 fusion; they may include TP53 mutation, p16 overexpression, and telomerase reverse transcriptase (TERT) promoter alterations. 22, 31, 33, 34 In addition to tumor size and the other worrisome pathologic characteristics that have been incorporated into the various grading schemes, clinical factors have also been associated with increased risk of recurrence; they include symptomatic presentation, pleural effusion, presence of fibrous adhesions, and incomplete resection. 23, 28 Complete surgical resection is the preferred treatment for all SFTs regardless of risk prediction, with an overall longterm cure rate for all patients between 88% to 92%. 35 The treatment of histologically high-risk, recurrent, or metastatic SFTs has not been well established owing to the rarity of these events. However, complete resection is still the preferred therapy in these cases, with a possible role for chemotherapy and/ or radiation therapy. 35, 36 There was no established adjuvant therapy regiment in our population; however, both chemotherapy and radiation therapy were utilized with limited success in patients with significantly advanced or inoperable recurrent disease. The scoring systems that we reviewed were evaluated for their prognostic capabilities, namely, the prediction of recurrence or metastasis. Given that all subjects in our series underwent resection and given the lack of clearly beneficial and widely accepted adjuvant therapy after complete resection, we cannot comment on the predictive capabilities of these systems or make therapeutic recommendations based on individualized scores at this time. Regardless, a better understanding of the risk and patterns of recurrence may help surgeons and oncologists counsel their patients appropriately. Furthermore, with the possibility of late recurrence, long-term follow-up with imaging surveillance is considered for most patients, and those with the highest risk of recurrence may potentially benefit from more frequent surveillance, as others have recommended. 18 Multi-institutional approaches or big data analyses followed by confirmatory studies to define optimal score-based surveillance and treatment recommendations will likely be required.
In addition to the limitations expected because of our retrospective study design, a major limitation of our study is the limited number of recurrence and metastases, which precluded multivariate analysis. Given that most SFTs do not lead to patient death, PFS may be a more realistic end point than OS. However, the recurrence rate is low, such that accrual of a study population size sufficient to generate meaningful statistics is challenging. Furthermore, time to recurrence may outlast the surveillance period, even in studies such as ours, in which the median follow-up was more than 5 years. Baldi et al. 1 found a median time to recurrence of 12 years after the primary lesion, and thus long-term follow-up is recommended for all patients with this diagnosis.
In summary, most SFTs follow a benign clinical course, but a subset will recur or metastasize, with an estimated 5-year progression rate of 8.5%. Therefore, complete surgical excision is recommended for all patients with SFT, and long-term follow-up is prudent. Among the most recently proposed risk stratification systems, the proposals by Demicco and Tapias have been successful in predicting both PFS and OS. The modified Demicco scoring system has the major advantages of simplicity and applicability to SFTs from other sites, and it had the best discriminatory power in our study.
